CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences: Jefferies Global... Read More

Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage... Read More

CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the Citizens Life Sciences Conference on May 7 and the... Read More

CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company’s Board of Directors. Mr. Hoerter brings over three decades of... Read More

CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 24th Annual Needham Virtual Healthcare Conference.... Read More

Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025 MBX 1416 Phase 2 trial in patients with post-bariatric hypoglycemia expected to begin in 2H 2025 Investigational New Drug submission anticipated in Q2 2025 for MBX 4291 in obesity $262.1 million in cash, cash equivalents and marketable securities as of December 31, 2024; expected to support operations into... Read More

Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Quality CARMEL, Ind., March 05, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders,... Read More

CARMEL, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of enrollment in its Phase 2 Avail™ trial of MBX 2109 (canvuparatide), the Company’s parathyroid hormone (PTH) peptide prodrug.... Read More

CARMEL, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences: TD Cowen 45th Annual... Read More

CARMEL, Ind., Jan. 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at, and participate in, the following upcoming investor conferences:... Read More

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET... Read More

CARMEL, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14... Read More

CARMEL, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the Company’s parathyroid hormone (PTH) peptide... Read More

CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject’s last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company’s long-acting... Read More

Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject last visit in Phase 1 trial of MBX 1416 anticipated by late November; topline results to be reported in early January 2025 Enrollment of Phase 2 Avail™ trial of MBX 2109 in hypoparathyroidism on track to complete in Q1 2025; topline results anticipated in Q3 2025 Strong cash position, with $277.1... Read More

CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc . (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences: Guggenheim Inaugural Healthcare Innovation Conference Date:... Read More

CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that both the rationale and design of the Phase 2 Avail™ trial of MBX 2109, the Company’s potential long-acting parathyroid hormone (PTH) peptide... Read More

CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the closing of its previously announced upsized initial public offering of 11,730,000 of its common stock at a price to the... Read More

CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its initial public offering of 10,200,000 shares of its common stock at a price to the public of $16.00 per share.... Read More

CARMEL, Ind., September 9, 2024 (GLOBE NEWSWIRE) – MBX Biosciences, Inc. (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the launch of its initial public offering of 8,500,000 shares of its common stock pursuant to a registration statement filed with the... Read More